BMS offloads imaging unit for $525M

Bristol-Myers Squibb said it was going to retrench, and so it is. The company announced this morning that it would sell its medical imaging unit to the private equity firm Avista Capital Partners for about $525 million. BMS says it wants to focus more narrowly on biopharma, which doesn't include medical imaging. Plus, the unit's biggest product, Cardiolite, faces generic competition after its key patent expires next year.

The sale is part of a company-wide restructuring that includes 4,300 layoffs; BMS hopes to save $1.5 billion a year from cuts in jobs and manufacturing.

- take a look a this release from BMS
- read this article for more

Related Articles:
BMS cuts 4,800 jobs. Report
BMS starts laying off workers. Report
BMS to unveil (big?) layoffs. Report
Bristol CEO: Job cuts, shutdowns continue. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.